This MedLibrary.org supplementary page on Flutoprazepam is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Flutoprazepam
|
|
| Systematic (IUPAC) name | |
| 7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H16ClFN2O |
| Mol. mass | 342.795 |
| Pharmacokinetic data | |
| Bioavailability | 80-90% |
| Metabolism | Hepatic |
| Half life | 60-90 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) |
| Legal status |
Schedule IV(US) |
| Routes | Oral, Intravenous |
Flutoprazepam (Restas, KB-509) is a drug which is a benzodiazepine derivative. It was invented in Japan in 1972, and its medical use remains mostly confined to that country. Its muscle relaxant properties are approximately equivalent to those of diazepam - however, it has powerful sedative, hypnotic, anxiolytic and anticonvulsant effects and is around four times more potent by weight compared to diazepam. [1] It is longer acting than diazepam due to its long-acting active metabolites,[2] which contribute significantly to its effects.[3]
Flutoprazepam is used for the treatment of insomnia and may also be used for treating stomach ulcers.[4]
Abuse of benzodiazepines in Japan is extremely common, with flutoprazepam being one of the most commonly abused, along with the benzodiazepines of abuse nimetazepam and temazepam. As of late 2007, the Japanese government is considering placing nimetazepam and temazepam into a more restrictive drug schedule. It is unknown as of yet whether flutoprazepam will be subject to the same controls. Triazolam, oxazepam, and nitrazepam are also very common benzodiazepines of abuse in Japan.citation needed
References
- ^ Sukamoto T, Aikawa K, Itoh K, Nose T. Psychopharmacological and general pharmacological studies of 7-chloro-1-cyclopropylmethyl-1, 3-dihydro-5-(2-fluorophenyl)-2H-1, 4-benzodiazepin-2-one (KB-509). Nippon Yakurigaku Zasshi. 1980 Sep;76(6):447-68. (Japanese).
- ^ Ueki S, Sukamoto T, Watanabe S, Yamamoto T, Kataoka Y, Shibata S, Suwandi D, Shibata K, Takano M, Sato Y. Behavioral effects of flutoprazepam (KB-509) and its metabolites. Nippon Yakurigaku Zasshi. 1982 Jul;80(1):15-30. (Japanese).
- ^ Barzaghi N, Leone L, Monteleone M, Tomasini G, Perucca E. Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects. European Journal of Drug Metabolism and Pharmacokinetics. 1989 Oct-Dec;14(4):293-8.
- ^ Fukuda T, Itoh K, Nose T. Antiulcerogenic action of 7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one (KB-509), a new benzodiazepine derivative. Nippon Yakurigaku Zasshi. 1981 Mar;77(3):273-80. (Japanese).
|
|||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 17 March 2008, at 01:40.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Flutoprazepam".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.